[go: up one dir, main page]

MX2020008699A - Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo. - Google Patents

Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo.

Info

Publication number
MX2020008699A
MX2020008699A MX2020008699A MX2020008699A MX2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A MX 2020008699 A MX2020008699 A MX 2020008699A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
solution
amino
eye drop
Prior art date
Application number
MX2020008699A
Other languages
English (en)
Inventor
Dong-Yeop Shin
Hu-Seong Kim
Geun-Hyeog Lee
Kyung-Joon Kim
Yun-Seok Cho
O Mi-Jin
Mi-Jung Kim
Original Assignee
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd filed Critical Hanlim Pharmaceutical Co Ltd
Publication of MX2020008699A publication Critical patent/MX2020008699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)

Abstract

La presente invención proporciona una formulación de gotas para los ojos en forma de una solución, que comprende (2R,3R,4S)-6-amino-4-[N-(4-clorofenil)-N-(1H-imidazol-2-ilmetil)a mino]- 3-hidroxi-2-metil-2-dimetoximetil-3,4-dihidro-2H-1-benzopir ano o una sal farmacéuticamente aceptable del mismo; propilenglicol como agente estabilizante; y un agente de control de pH en un medio acuoso, en donde la formulación de gotas para los ojos tiene un pH que varía de 4.0 a 5.0. La formulación de gotas para los ojos de la presente invención puede contener (2R,3R,4S)-6-amino-4-[N-(4-clorofenil)-N-(1Himidazol- 2-ilmetil)amino]-3-hidroxi-2-metil-2-dimetoximetil-3,4-dihidro-2H -1-benzopirano o una sal farmacéuticamente aceptable del mismo en una alta concentración; y tiene una excelente estabilidad. Además, el producto farmacéutico para prevenir o tratar la degeneración macular según la presente invención puede almacenarse durante períodos prolongados.
MX2020008699A 2018-02-28 2019-02-18 Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo. MX2020008699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180024470A KR102478553B1 (ko) 2018-02-28 2018-02-28 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제
PCT/KR2019/001894 WO2019168289A1 (ko) 2018-02-28 2019-02-18 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제

Publications (1)

Publication Number Publication Date
MX2020008699A true MX2020008699A (es) 2020-09-25

Family

ID=67805843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008699A MX2020008699A (es) 2018-02-28 2019-02-18 Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo.

Country Status (16)

Country Link
US (1) US11771647B2 (es)
EP (1) EP3760188B1 (es)
JP (1) JP7160934B2 (es)
KR (1) KR102478553B1 (es)
CN (1) CN111801094B (es)
AU (1) AU2019226830B2 (es)
BR (1) BR112020017497A2 (es)
CA (1) CA3089091C (es)
ES (1) ES2953040T3 (es)
MX (1) MX2020008699A (es)
MY (1) MY198945A (es)
NZ (1) NZ766624A (es)
PH (1) PH12020551194A1 (es)
SG (1) SG11202007054VA (es)
WO (1) WO2019168289A1 (es)
ZA (1) ZA202005891B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250033790A (ko) * 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3969B (en) * 1994-03-15 1996-05-27 Senju Pharma Co Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen
JPH10236951A (ja) * 1996-12-27 1998-09-08 Teika Seiyaku Kk プラノプロフェン配合点眼剤
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
JP2011011984A (ja) * 2009-06-30 2011-01-20 Lion Corp 仮性近視治療薬
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
WO2014121027A1 (en) * 2013-02-01 2014-08-07 Oculars Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof

Also Published As

Publication number Publication date
US20200405634A1 (en) 2020-12-31
EP3760188B1 (en) 2023-06-14
KR102478553B1 (ko) 2022-12-16
EP3760188A4 (en) 2021-10-20
JP7160934B2 (ja) 2022-10-25
EP3760188A1 (en) 2021-01-06
AU2019226830A1 (en) 2020-08-13
US11771647B2 (en) 2023-10-03
PH12020551194A1 (en) 2021-08-16
RU2020125724A3 (es) 2022-04-29
ES2953040T3 (es) 2023-11-07
BR112020017497A2 (pt) 2020-12-22
AU2019226830B2 (en) 2024-01-11
EP3760188C0 (en) 2023-06-14
CA3089091C (en) 2025-05-27
CN111801094B (zh) 2022-11-18
MY198945A (en) 2023-10-03
CA3089091A1 (en) 2019-02-18
CN111801094A (zh) 2020-10-20
SG11202007054VA (en) 2020-08-28
ZA202005891B (en) 2022-03-30
JP2021514995A (ja) 2021-06-17
NZ766624A (en) 2025-10-31
KR20190103710A (ko) 2019-09-05
RU2020125724A (ru) 2022-03-28
WO2019168289A1 (ko) 2019-09-06

Similar Documents

Publication Publication Date Title
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
ATE428401T1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
AR107014A1 (es) Formulación farmacéutica acuosa
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
CL2020002252A1 (es) Formulación oftálmica.
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
EA201490803A1 (ru) Составы этанерцепта, стабилизированные ксилитом
AR091308A1 (es) Nanoparticulas que comprenden una proteina hidrofoba vegetal y un disolvente organico no volatil miscible en agua y usos de las mismas, procedimiento, composicion
GT201200069A (es) Formulaciones farmacéuticas muy concentradas
AR112103A1 (es) Compuestos para el tratamiento de tnbc
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
AR105199A1 (es) Soluciones oftálmicas acuosas
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
MX2020008699A (es) Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo.
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
MX2015008528A (es) Formulaciones para conservacion de organos y tejidos con estabilidad y vida util aumentadas.
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
BR112019000897A2 (pt) sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão.
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
MX2016006651A (es) Soluciones para incrementar la estabilidad y la vida util de una solucion de conservacion de organos y tejidos.
ES2531241T3 (es) Composición farmacéutica líquida estable a base de trazodona
MX2021013405A (es) Estabilizacion de concentrados en suspension mediante ricinoleina etoxilada.
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla